S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-10-01
|
| Series: | Lupus Science and Medicine |
| _version_ | 1811195140084072448 |
|---|---|
| author | S Banerjee S Singhal V Shah R Van Vollenhoven M Pike E Morand I Catlett VP Werth JT Merrill N Delev C Hobar B Sharkey T Wegman |
| author_facet | S Banerjee S Singhal V Shah R Van Vollenhoven M Pike E Morand I Catlett VP Werth JT Merrill N Delev C Hobar B Sharkey T Wegman |
| author_sort | S Banerjee |
| collection | DOAJ |
| first_indexed | 2024-04-12T00:38:30Z |
| format | Article |
| id | doaj.art-7202d674bb32434b9924687621ef56bc |
| institution | Directory Open Access Journal |
| issn | 2053-8790 |
| language | English |
| last_indexed | 2024-04-12T00:38:30Z |
| publishDate | 2022-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj.art-7202d674bb32434b9924687621ef56bc2022-12-22T03:55:05ZengBMJ Publishing GroupLupus Science and Medicine2053-87902022-10-019Suppl 210.1136/lupus-2022-elm2022.23S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled studyS Banerjee0S Singhal1V Shah2R Van Vollenhoven3M Pike4E Morand5I Catlett6VP Werth7JT Merrill8N Delev9C Hobar10B Sharkey11T Wegman12Paediatric Department, Bedford Hospital NHS Trust, Bedford, UK1Child Development, KK Women’s and Children’s Hospital, Singapore, Singapore1Radiology and Biomedical Imaging, UCSF, San Francisco, CA5 Karolinska University Hospital, Stockholm, Sweden11Department of Paediatric Neurology, Oxford University Hospitals NHS Trust, Oxford, UK4Monash University, Melbourne, AustraliaVertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, USA3Corporal Michael J. Crescenz Veterans Affairs, Medical Centre Philadelphia PA, Philadelphia, USA1Oklahoma Medical Research Foundation, Clinical Pharmacology, Oklahoma, USA1Bristol Myers Squibb ~ Lawrenceville, NJ ~ USA6Bristol Myers Squibb ~ Princeton ~ USA6Bristol Myers Squibb ~ Princeton ~ USA6Bristol Myers Squibb ~ Princeton ~ USA |
| spellingShingle | S Banerjee S Singhal V Shah R Van Vollenhoven M Pike E Morand I Catlett VP Werth JT Merrill N Delev C Hobar B Sharkey T Wegman S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study Lupus Science and Medicine |
| title | S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study |
| title_full | S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study |
| title_fullStr | S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study |
| title_full_unstemmed | S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study |
| title_short | S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study |
| title_sort | s11 2 efficacy and safety of deucravacitinib a selective tyk2 inhibitor in patients with active systemic lupus erythematosus results from a phase 2 randomized double blind placebo controlled study |
| work_keys_str_mv | AT sbanerjee s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT ssinghal s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT vshah s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT rvanvollenhoven s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT mpike s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT emorand s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT icatlett s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT vpwerth s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT jtmerrill s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT ndelev s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT chobar s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT bsharkey s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy AT twegman s112efficacyandsafetyofdeucravacitinibaselectivetyk2inhibitorinpatientswithactivesystemiclupuserythematosusresultsfromaphase2randomizeddoubleblindplacebocontrolledstudy |